000 01855nam  2200373zi 4500
0019.936485
003CaOODSP
00520240607103024
006m     o  d f      
007cr mn|||||||||
008240408t20242024onc     ob   f000 0 eng d
020 |a9780660712529|q(Statement)
020 |a9780660712536|q(Summary)
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aHP40-362/1-2024E-PDF
0861 |aHP40-362/2-2024E-PDF
24500|aInterim guidance on the use of Imvamune in the context of a routine immunization program.
264 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |c2024.
264 4|c©2024
300 |a1 online resource (29 pages) + |esummary (5 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aCover title.
500 |aIssued also in French under title: Directives provisoires du CCNI sur l'utilisation d'Imvamune dans le cadre d'un programme de vaccination systématique.
500 |aAt head of title: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).
500 |aTitle appears with a registered symbol after the word “Imvamune”.
504 |aIncludes bibliographical references.
650 0|aMpox (Disease)|xVaccination|zCanada.
7102 |aPublic Health Agency of Canada, |eissuing body.
77508|tDirectives provisoires du CCNI sur l'utilisation d'Imvamune dans le cadre d'un programme de vaccination systématique.|w(CaOODSP)9.936486
85640|qPDF|s814 KB|uhttps://publications.gc.ca/collections/collection_2024/aspc-phac/HP40-362-1-2024-eng.pdf|z(Statement)
85640|qPDF|s485 KB|uhttps://publications.gc.ca/collections/collection_2024/aspc-phac/HP40-362-2-2024-eng.pdf|z(Summary)